QUANTITATIVE METHODS FOR EVALUATING THE PROCESS ACTIVITY IN THE DIAGNOSIS AND TREATMENT OF T-CELLULAR SKIN LYMPHOMAS

V. A Moiochkov; A. M Kovrigina; A. V Moiochkov; A. V Karaulov; G. V Menshchikova; A. V Fedorovskaya; I. V Yefimovich

doi:10.17816/dv36723

Russian Journal of Skin and Venereal Diseases ›› 2012, Vol. 15 ›› Issue (5) : 4 -7. DOI: 10.17816/dv36723

Articles

research-article

QUANTITATIVE METHODS FOR EVALUATING THE PROCESS ACTIVITY IN THE DIAGNOSIS AND TREATMENT OF T-CELLULAR SKIN LYMPHOMAS

Author information +

History +

PDF

Abstract

Precise standardized measurements are essentialfor the diagnosis and treatment of Sezary ’s syndrome (mycosis fungoides). The T-cellular skin lymphoma (T-CSL) severity index (SI) has been suggested in 2005. Evaluation of this index is a simple to use quantitative indicator of the disease activity in cases with involvement of many organs and systems (skin, lymph nodes, circulatory system, viscera) and a prognostically significant characteristic in multifactorial analysis. The index, quantitatively reflecting the disease activity in all involved organs and systems, effectively supplements the TNM classification in clinical practice and research.

Keywords

T-cellular skin lymphoma / mycosis fungoides / prognostic significance / prognostic factors / prognostic index / severity index / Sezary ’s syndrome / survival

Cite this article

Download citation ▾

V. A Moiochkov, A. M Kovrigina, A. V Moiochkov, A. V Karaulov, G. V Menshchikova, A. V Fedorovskaya, I. V Yefimovich. QUANTITATIVE METHODS FOR EVALUATING THE PROCESS ACTIVITY IN THE DIAGNOSIS AND TREATMENT OF T-CELLULAR SKIN LYMPHOMAS. Russian Journal of Skin and Venereal Diseases, 2012, 15(5): 4-7 DOI:10.17816/dv36723

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Criscione V.D., Weinstock M.A. Incidence of cutaneous T-cell lymphoma in the United States, 1973—2002. Arch Dermatol. 2007; 143(7): 854—9.

[2]	Willemze R., Jaffe E.S., Burg G., Cerroni L., Berti E., Swerdlow S.H., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105(10): 3768—85.

[3]	Bunn P.A.Jr., Lamberg S.I. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep. 1979; 63(4): 725—8.

[4]	Kim E.J., Hess S., Richardson S.K., Newton S., Showe L.C., Benoit B.M., et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J. Clin. Invest. 2005; 115(4): 798—812.

[5]

Kim Y., Reddy S., Kim E.J. et al. Romidepsin (depsipeptide, FK228) induces clinically significant responses in treatment-refractory CTCL: further report of an international, multicenter study. Oral presentation at: American Society of Hematology Meeting, Atlanta, Dec 8—11, 2007. ISSN: 0190-9622. doi: 10.1016/j.jaad.2007.01.044.

[6]	Dippel E., Goerdt S., Assaf C., Stein H., Orfanos C.E., et al. Cutaneous T-cell lymphoma severity index and T-cell gene rearrangement. Lancet 1997; 350(9093): 1776—7.

[7]

Olsen E., Vonderheid E., Pimpinelli N., Willemze R., Kim Y., Knobler R., et al.; ISCL/EOrTc. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110(6): 1713—22.

[8]	Stevens S.R., Ke M.S., Parry E.J., Mark J., Cooper K.D. Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT). Arch. Dermatol. 2002; 138(1): 42—8.

[9]	The National Comprehensive Cancer Network mycosis fungoides/Sezary syndrome clinical practice guidelines in oncology (version 3.2008) Available from: URL. Accessed December 4, 2008. http://www.nccn.org.